Fedratinib hydrochloride hydrate
Cat. No.：YN340055
CAS No. ：1374744-69-0
| 产品名称: | Fedratinib hydrochloride hydrate |
| CAS No.: | 1374744-69-0 |
| Chemical Name: | |
| Synonyms: | TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate |
| 分子量: | 615.62 |
| 分子式: | C₂₇H₄₀Cl₂N₆O₄S |
| SMILES: | [H]Cl.[H]O[H].[H]Cl.O=S(C1=CC=CC(NC2=NC(NC3=CC=C(C=C3)OCCN4CCCC4)=NC=C2C)=C1)(NC(C)(C)C)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) 是一种有效的，选择性的，ATP 竞争性和具有口服活性的JAK2抑制剂，对于JAK2和JAK2V617F激酶的IC50均为 3 nM。Fedratinib hydrochloride hydrate 对JAK2的选择性分别比 JAK1 和 JAK3 高 35 倍和 334 倍。Fedratinib hydrochloride hydrate 可诱导癌细胞凋亡 (apoptos |
| IC50和靶点: | [{name:"JAK2:3 nM (IC50)"},{name: "JAK2(V617F):3 nM (IC50)"},{name: "Flt3:15 nM (IC50)"},{name: "Ret:48 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
